Claims for Patent: 7,129,274

Summary for Patent: 7,129,274

Title:	Phenoxy carboxylic acid compounds and compositions for delivering active agents
Abstract:	Phenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
Inventor(s):	Leone-Bay; Andrea (Ridgefield, CT), Kraft; Kelly (Hopewell Junction, NY), Moye-Sherman; Destardi (Newburgh, NY), Gschneidner; David (Stamford, CT), Boyd; Maria A. P. (Garrison, NY), Liu; Puchun (Somers, NY), Tang; Pingwah (Elmsford, NY), Liao; Jun (Yorktown Heights, NY), Freeman, Jr.; John J. (New Fairfield, CT), Smart; John E. (Katonah, NY)
Assignee:	Emisphere Technologies Inc. (Tarrytown, NY)
Application Number:	10/129,467
Patent Claims:	1. A compound having the formula ##STR00002## or a salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are H; R.sup.5 is --OH; R.sup.6 is a C.sub.4-C.sub.12 alkylene; and R.sup.7 is a bond. 2. A compound selected from the group consisting of TABLE-US-00013 ##STR00003## Cpd # R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 R.sup.6 R.sup.7 5 H H H H OH (CH.sub.2).sub.5 bond 6 H H H H OH (CH.sub.2).sub.6 bond 7 H H H H OH (CH.sub.2).sub.7 bond 8 H H H H OH (CH.sub.2).sub.9 bond 43 H OH H H H (CH.sub.2).sub.7 bond 44 H OH H H H (CH.sub.2).sub.9 bond 45 H OH H H H (CH.sub.2).sub.5 bond 46 H OH H H H (CH.sub.2).sub.3 bond 47 H H OH H H (CH.sub.2).sub.7 bond 48 H H OH H H (CH.sub.2).sub.9 bond and salts thereof. 3. A compound having the formula ##STR00004## or a salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.5 are H; R.sup.4 is OH; R.sup.6 is a C.sub.2-C.sub.12 alkylene; and R.sup.7is a bond. 4. A compound having the formula ##STR00005## or a salt thereof, wherein R.sup.1, R.sup.2, R.sup.4, and R.sup.5 are H; R.sup.3 is OH; R.sup.6 is a C.sub.6-C.sub.9 alkylene; and R.sup.7is a bond. 5. A compound having the formula ##STR00006## and salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are H; R.sup.5 is OH; R.sup.6 is a C.sub.1 alkylene; and R.sup.7 is a bond. 6. A compound having the formula ##STR00007## or a salt thereof, wherein R.sup.1, R.sup.2, R.sup.4, and R.sup.5 are H; R.sup.3 is OH; R.sup.6 is a C.sub.11-C.sub.12 alkylene; and R.sup.7 is a bond. 7. The compound of claim 2, wherein the compound is selected from: TABLE-US-00014 ##STR00008## Cpd # R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 R.sup.6 R.sup.7 43 H OH H H H (CH.sub.2).sub.7 bond 44 H OH H H H (CH.sub.2).sub.9 bond 45 H OH H H H (CH.sub.2).sub.5 bond 46 H OH H H H (CH.sub.2).sub.3 bond 47 H H OH H H (CH.sub.2).sub.7 bond and salts thereof. 8. The compound of claim 7, wherein the compound is selected from: TABLE-US-00015 ##STR00009## Cpd # R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 R.sup.6 R.sup.7 47 H H OH H H (CH.sub.2).sub.7 bond and salts thereof. 9. A composition comprising: (A) at least one biologically active agent; and (B) at least one compound of claim 1. 10. A composition comprising: (A) at least one biologically active agent; and (B) at least one compound of claim 2. 11. The composition of claim 10, wherein the biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, polar organic molecules, or lipid. 12. The composition of claim 10, wherein the biologically active agent is selected from the group consisting of: growth hormones, human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone-releasing hormones, interferons, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor(IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine, parathyroid hormone, fragments of parathyroid hormone, antimicrobials, daptomycin, anti-fungal agents, vitamins; and any combination thereof. 13. The composition of claim 12, wherein the biologically active agent comprises insulin, unfractionated heparin, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, parathyroid hormone, erythropoietin, daptomycin, human growth hormones, or any combination thereof. 14. The composition of claim 13, wherein the biologically active agent comprises calcitonin. 15. The composition of claim 13, wherein the compound has the formula TABLE-US-00016 ##STR00010## Cpd # R.sup.1 R.sup.2 R.sup.3 R.sup.4 R.sup.5 R.sup.6 R.sup.7 43 H OH H H H (CH.sub.2).sub.7 bond. 16. A dosage unit form comprising: (A) the composition of claim 10; and (B) (a) an excipient (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof. 17. The dosage unit form of claim 16, wherein the biologically active agent comprises at least one protein, polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, polar organic molecules, carbohydrate, or lipid. 18. The dosage unit form of claim 16, wherein the biologically active agent is selected from the group consisting of: growth hormones, human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone-releasing hormones, interferons, .alpha.-interferon, .beta.-interferon, .gamma.-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor(IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, antimicrobials, daptomycin, anti-fungal agents, vitamins, and any combination thereof. 19. The dosage unit form of claim 18, wherein the biologically active agent comprises insulin, unfractionated heparin, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, parathyroid hormone, erythropoietin, human growth hormones, or any combination thereof. 20. The dosage unit form of claim 19, wherein the biologically active agent comprises calcitonin. 21. The dosage unit form of claim 16, wherein the dosage unit form comprises a tablet, a capsule, a powder, or a liquid. 22. A method of increasing the bioavailability of a biologically active agent comprising orally administering to an animal in need thereof the composition of claim 10. 23. A method for preparing a composition comprising mixing: (A) at least one biologically active agent; (B) at least one compound as claimed in claim 2; and (C) optionally, a dosing vehicle.

Details for Patent 7,129,274

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2019-11-05
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2019-11-05
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2019-11-05
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2019-11-05
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2019-11-05
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2019-11-05
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2019-11-05